Bupropion as a modulator of drug activity
First Claim
1. A method of enhancing dextromethorphan plasma levels in a human being, comprising co-administering a bupropion with a dextromethorphan, to the human being, for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein the weight ratio between the dextromethorphan and the bupropion is about 0.4 to about 0.7, and wherein, on the eighth day that the bupropion and the dextromethorphan are co-administered, the AUC0-12 of dextromethorphan is at least about 15 times the AUC0-12 of dextromethorphan that would result from administering the same amount of the dextromethorphan without the bupropion for eight consecutive days.
1 Assignment
0 Petitions
Accused Products
Abstract
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
-
Citations
29 Claims
- 1. A method of enhancing dextromethorphan plasma levels in a human being, comprising co-administering a bupropion with a dextromethorphan, to the human being, for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein the weight ratio between the dextromethorphan and the bupropion is about 0.4 to about 0.7, and wherein, on the eighth day that the bupropion and the dextromethorphan are co-administered, the AUC0-12 of dextromethorphan is at least about 15 times the AUC0-12 of dextromethorphan that would result from administering the same amount of the dextromethorphan without the bupropion for eight consecutive days.
- 17. A method of treating a human being in need of treatment with dextromethorphan, comprising administering a bupropion with a dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan, wherein the bupropion is administered in an amount that results in a Cavg of dextromethorphan on the eighth day of at least about 25 ng/mL, and wherein, on the eighth day that the bupropion and the dextromethorphan are co-administered, the AUC0-12 of dextromethorphan is at least about 15 times the AUC0-12 of dextromethorphan that would result from administering the same amount of the dextromethorphan without the bupropion for eight consecutive days.
Specification